Summary: This paper describes the field performance of the Kodak EKTACHEM GLU/BUN Analyzer for glucose and urea. NCCLS protocols PSEP-2,3 and 4 were used which enable manufacturers to establish perfonnance Claims concerning the precision and accuracy of an analytical System. This multicentre trial used four analysers in four European countries, United Kingdom, France, West Germany and Italy to assess within and between laboratory performances.
Introduction
The Kodak EKTACHEM analytical System (l, 2) has recently been introduced into the field of clinical chemistry and Kodak EKTACHEM GLU/BUN Analyzers for glucose and urea analyses are now in routine use in a number of hospitals in the United States of America.
As part of the programme for testing the field performance of the analytical System, four hospital laboratories in the United Kingdom, France, West Gerinany and Italy used four separate analysers run according to the manufacturers "Operators Manual" (3) over the same period of time to carry out studies using the National Committee for Clinical Laboratory Standards (NCCLS) Protocol for Establishing Performance Claims for Clinical Chemistry Methods (PSEP-2, 3 and 4) (4).
A previous evaluation of the Kodak EKTACHEM products has been published (5) . The earlier NCCLS protocol PSEP-1 was available at that time but the study was not on a multicentre basis. In this study the same materials and protocols were used (apart from patient samples) in all the v laboratories and this provided a unique opportunity to assess within and between laboratory performance of Kodak EKTACHEM products and to obtain practical experience using the protocoL Since it is essential that manufacturers work jointiy with hospitals in the use of these protocols to establish performance Claims we have included comments on their practicability.
Materials and Methods

NCCLS protocol for establishing Performance Claims for Clinical Chemistry methods
The protocol is in three sections (4) . The sections and the materials used are described below.
Performance Check Experiment PSEP-2
The protocol describes the control material to be used and suggests that the materials selected should simulate the chaiacteristics of human sera äs closely äs possible. HIGH, MID and LOW concentrations should contain where possible analytes at concentrations near the top of the linear ränge of the method, near the middle of the ränge for healthy people and neär the bottom of the linear ränge of the method. Construction of control charts is described and these were established for the test methods on the four sites and used thioughout subsequent evaluation experiments. Triplicate anaiyses of the three levels were run on forty occasions during the familiarisation period. The control sera used were lyophilised human material provided by Kodak for the LOW and the HIGH-levels and Wellcpmtrol II (Wellcome Reagents Ltd., Kent, U.K.) for the MID level. This data was used to construct mean and ränge charts. The mean charts consist of a grand mean with upper and lower control limits at ± 3 Standard deviätions. Range is defined äs the difference between the highest and lowest of triplicate readings. The overall mean ränge is calculated with a control limit set at 2.57 times the mean ränge.
Replication Experiment PSEP-3
The criteria for choice of material at HIGH, MID and LOW levels is äs described for PSEP-2. Nine sample sets of HIGH, MID and LOW levels arelrün after the performance check samples. The sample sets for the maxi, midi and mini experiments are shown in table 1. The ordef of the nine sample sets are chosen from random permutations provided in the protocol. The replication (imprecisipn) protocol specifies a period of twenty days and a total of forty analytical runs. The midi Version was chosen because it detected carry over effects and provided estimates of within run, between run within day, between runs between day and total imprecisipn. For each concentration level studied two different estimates öf within run .and total imprecision are reqüired for presentation of performance Claims. The first, designated point estiriiate, is the actual Standard deviation obserVed in the experiment performed and the second, designated tolerance limit, represents the upper limit that with 95% confidence will contain the estimate of Standard deviation from 99% of all similar experiments.
Tab. Sample number
The replication experiment used the three controls from the performance check period tpgether with Pathonorm L (Nygaärd, BDH Ppole, England) Wellcomtrol I (Wellcome Reagents Ltd, Beckenham, England) and GEO A632 (General Diagnostics, New Jersey, USA).
Comparison of Methods Experiment PSEP-4
In this experiment patient specimens are analysed by both the test method and a comparative analytical method. A suggested concentration distribution pf specimens for a number of analytes is given in the protocol. Table 2 gives the suggested distribution and the actual distribution used for urea and glucose specimens. the comparative methods used by each labpratory, the type Pf the specimens collected, storage conditions and individual modifications to the protocol are given in the test for outliers whereby up to three pairs showing a difference of greater than 3.5 times Sy x can be excluded before the final regression analysis. Set D gives the analysis of Wellcome sera.
The regression statistics obtained on data set (C) are used to calculate average bias (yc-xc, where yc is the test method value at medical decision concentration xc) at different medical decision concentrations. Tolerance limits are caleulated for yc so that there is a 99% probabüity that 95% of the samples are included within the upper and lower limits and total error is estimated äs the absolute value of the largest difference between the tolerance limits and xc. It is recommended that the tolerance limits and total error be caleulated only for medical decision concentrations closest to the mean of the comparative method results. It has been recommended that the linear regression procedures should be restricted to those cases where the correlation coefficient (r) exceeds 0.99 (6) or that the ränge of values used is adequate when the Standard deviation of the comparative method values (SD X ) is greater than seven time (Sy X ) (7) . Values for both r and SD x /s yx are included with regression statistics.
Wellcome Group Quality Control Programme The multi-level lyophilised material available from the programme was used, firstly to obtain Information on the performance of comparative methods in each laboratory relative to that obtained by previous participants in the scheme, secondly to provide Information on the performance of the EKTACHEM analyzer from laboratory to laboratory, and thirdly to give comparison data additional to that from patient specimens. Samples previously sent out by the scheme from 16 October 1978-26 March 1979 were analysed by the comparative and Kodak methods at each site. Two dupücate sets of twelve lyophilised bovine sera were provided and a sample for analysis taken from each of the twenty-four bottles after reconstitution, giving twelve duplicate analyses for each analyte. Analysis of the twelve samples by laboratories participating in the scheme is normally spread over a six month period and the analysis of results returned includes the overall mean for each analyte, that is the mean of all results returned, with results greater than three Standard deviations from the mean excluded, and method means which represent the mean of all results from laboratories with a particular method classification. The overall mean values in the samples used ranged from 3.40 to 13.77 mmöl/1 for glucose and for urea from 5.21 to 23.61 mmol/1. The material in the scheme came from four pools. Different amounts of serum are dispensed to provide each sample and äs an identical volume of fluid is recommended for reconstitution this results in different analyte concentrations. Tables 4 and 5 give the analysis of variance (ANOVA) results for the replication experiment. These tables include the mean value (mmol/1) of the concentration level studied, the point estimates of Standard deviation and degrees of freedom (df). Tolerance limit estimates of Standard deviation are given for within run and total imprecision. Tables 6 and 7 give the regression statisties together with correlation coefficient and the ratio SD x /Sy X for patient samples used in the comparison of methods experiment. The preparation of data sets A, B and C is described in the Materials and Methods section. Regression statisties from data sets A and C were used to calcüiate the accuracy performance Claims given in 
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Discussion
Problems encountered with PSEP-2, 3 and 4
The establishment of performance Claims for Clinical Chemical Methods has become a major expense for manufacturers of clinical chemistry Systems and a time consuming occupation for skilled laboratory workers.
In these activities, however, there are complex problems, for manufacturers and clinical chemistry laboratories alike and the publication of proposed Standards PSEP-2,3 and 4 by the NCCLS represent an iniportant contribütion to progress in this field. This paper reports sojne of our experience with these Standards and the data derived from our work. The PSEP-2 and 3 Standards although time consuming, presented few difficulties in execution at the different sites. However, all siies encountered some difficulties in carrying out the proposed Standard for the Comparison of Methods Experiment (PSEP-4). The difficulties related on the one hand to the selection of patient specimens and their analysis according to the protocol and on the other hand to the performance of the comparative methods during the period of study.
The overview öf the Cqmparison of Methods Experiment suggests that "at least 100 fresh patient's specimens should be analysed in duplicate by both the test method and the comparative analytical method. The experiment must cover a period of at least 4 days, which permits a maximum of 25 specimens to be analysed in one day, or it can extend over a longer period of time if that is convenient for the evaluation stüdy". Recommendations for the selection öf patients specimens are given and one suggested distribution is shown in table 2.
It is clear that all sites encountered difficulties in selection of specimens and the laboratories in Italy and the U.K. were only able to comply with the suggested distribution by preselecting specimens and freezing them prior to subsequent duplicate analysis (tab. analysed the specimens in duplicate. The laboratory in France however ran nearly twice the number of specimens äs the other laboratories and äs a result regression estimates will not be markedly affected. However, only the German laboratory complied with the stipulation that the replicates should be in separate runs. One penalty of not running duplicates is the failure to produce within run estimates of imprecision for human sera for the test and comparative methods. The information is important for evaluation of the comparative method and for its comparison with the test method.
Additionally, these estimates of within run imprecision can be usefully compared with those obtained in the replication experiment using the lyophilised material. If the patient specimens in the German laboratory are replicated between run rather than within run, different estimates of precision are obtained which are not strictly comparable.
The amount of specimen required in order to perform duplicate analysis* by the test and comparative method represents a major problem if the test and/or comparative methods require substantial amounts of serum or plasma. The use of this protocol for evaluation of multichannel Systems may present special difficulties, although one such evaluation has recently been published (9) .
There is a tendency when selecting specimens for analysis to encounter difficulties at the ends of the ränge. This can lead to the multiple selection of specimens from one patient so that although the number of specimens required is fulfilled the variability represented by those specimens is reduced. If this were to become a major feature of selection then it might result in falsely low estimates of s yx which would markedly improve the accuracy performance Claims. It is interesting in this connection to compare the regression statistics for comparison of methods for the bovine material from the Wellcome Scheme (tabs 6 and 7 data sets D) with those obtained on patient specimens (data sets C). Bearing in mind the recognised problems associated with commutability of human specimens and samples from animal sources together with the small number of Wellcome samples used, the majority of estimates of slope and intercept are in good agreement with those obtained with patient specimens, However, the value for s yx in all laboratories for urea and glucose using Wellcome material is markedly lower than the value on patient specimens. This reflects the fact that the Wellcome material is taken from four homogenous pools and the smaller ränge covered.
If in excess of fifty quality control samples were used in a comparison of methods and commutability were satisfactory the Standard deviation of the estimates of slope and intercept would be markedly improved (8) but analysis of lyophilised material from different sources can never replace patient specimens in estimation of the Standard error of the regression line.
France used lithium heparin plasma specimens for glucose and urea analyses and the United Kingdom used fluoride oxalate plasma for glucose. Care r must be taken to ensure that plasma specimens prepared in this way are obtained from blood specimens which had the recommended amounts of anticoagulänt added. High concentrations, resulting from inadequate filling of a specimen Container, can adversely affect measurement by a test or comparative method.
The choice and control of the comparative method represents the second major probleih in the comparison of methods experiment and whereas the protocol discusses briefly the factors affecting the choice of ä comparative or reference method it does not provide guidance äs to the control of that method during the period of study. The data preserited in table 9 represents an attempt to provide some Information about the bias of the comparative methods. The significänt (95% confidence limits) positive intercept öf 0.4101 in the glucose data from Italy indicates the presence of constant error whereas the glucose data from France and the urea data from Italy indicate ä significänt proportional errpr in these methods when compared with their appropriate method means. When an individual laboratory results are compared with method means it must be remembered that the method mean codes used in this instance do not define a group of laboratories using a particular Instrument with a particular method but perhaps äs in the case of the code for the hexokinase/glucose method it contains on average 114 laboratories using Instruments from %t least nine different manufacturers some employing discrete analysis and some continuous flow. Therefore caution must be exercised when interpreting such a comparison.
Performance of the Kodak EKTACHEM GL tf/BUN Analyzer and preparation of Performance Claims
The Kodak EKTACHEM GLU/BUN änalyzer perfonned well on all sites äs judged by estimates of imprecision by using the proposed Standard PSEPJ (tab. 4 and 5) , and analysis of data from all laboratories indicates the veiy small contribution made to the overall variance by the laboratory to laboratory component. The differences in tolerance limits and estimates of total error (tab. 8) obtained from the comparison öf methods Standard PSEP-4 are influenced by the way in which data is analysed. The performance of the comparative methods is also important and makes a simultaneous multicentre study in evaluation of methods particularly valüäble when Claims for a product are put forward.
In the preparation of accuracy performance Claims it is ' clearthat calculation of bias is dependent on reliable estimates of slope and intercept and thfljt the tolerance limits are additionally dependent on the Standard error about the regression line (Sy X ). It is interesting in tables 6 and 7 to see that the rule goveming the exclusion of outliers can either eliminate or reduce outliers (compare data sets B with C) or because of the redefinition of s yx implicit in creating a new data set can lead to the same numbers of outliers still existing (see German data set B and C for glucose tab. 6). Preparation of data in the manner recommended will sometimes lead to a reduction in the ränge of samples analysed and additionally the rernoval of outliers will reduce the value of s xy . For Performance Claims to be comparable these factors must be taken into account. This effect can be seen by comparing the performance claims based on the whole data set A with those given for the prepared data set C. The protocol suggested that tolerance limits and total error be calculated only for medical decision eoncentrations closest to the mean of the comparative method data (x) table 8 shows that for glucose (data sets C) this requirement is reasonably well fulfdled. For the medical decision concentration of 6.6 mmol/1 values of ränge from 5.96 to 7.31 mmol/1. However for urea the Situation is less than satisfactory with mean values of ranging from 7.76 to 12.88 mmol/i for a medical decision concentration of 9.60 mmol/1. This problem has however already appeared in the litefatüre (9) with medical decision concentrations of 1100 mg/1 (6.1 mmol/1) for glucose having tolerance limits and total error quoted when the mean of comparative or reference method was 1670 mg/1 (9.3 mmol/1) and 1600 mg/1 (8.9 mmol/1) respectively and for a medical decision concentration of 250 mg/1 ((8.9 mmol/i) for ürea nitrogen with mean of at 512 mg/1 (18.3 mmol/1). It will be necessary to indicate how close is close if performance Claims are to be of value. The mean ofthe comparätive method (x) shoüld be given in an accuracy performance cläim in Order to avoid misunderstanding.
The Wellcome material was also üsed tö provide äddi-tional data on EKTACHEM products from site to site (tab. 10 and 11). The estimates of slope were significantly different from l .00 (95% confidence limits) for both urea and glucose between France and Italy whereas no significant differences from zero were observed for estimates of intercept. These differences are not however clearly reflected in the mean values of material used in the replicatiOn study (Tab. 4 and 5).
Conclusions
The proposed Standards PSEP-2,3 and 4 have proved a üseful basis on which to establish this multi-centre trial of the Kodak EKTACHEM GLU/BUN analyzer. The difficulties associated particularly with PSEP-4 have been fully discussed. It is suggested that the proposed Standard, PSEP-4 would be imprqved by inclusion of some basic criteria for evaluafion of the comparative method against other laboratories in form of methods means. It is in this area that manufacturers are most vulnerable to Claims made for or against their products by laboratories using inadequätely controlled comparative or reference techniques.
Because of the difficulties associated with obtaining patient samples and the labile nature of some analytes, manufacturers will always require the assistance of clinical chemistry laboratories in the establishment of performance Claims, but pur experience suggests, that this work shoüld not be undertaken lightly by laboratories and that manufacturers would be advised to assess the resources of any chosen site carefully befbre proceeding.
